Phase 3 Obesity Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Your sleep study (overnight breathing test) must show that you stop breathing or have disrupted breathing at least 15 times per hour.
- Your Body Mass Index (BMI) — a measure of weight relative to height — must be 27 or higher at the time of your initial check-up.
- You must have tried to lose weight through diet and exercise at least once in the past without lasting success.
- You must not have used a breathing machine (such as a CPAP machine) for at least 4 weeks before joining, and you must be unwilling or unable to use one, and not plan to use one during the study.
Who may not be able to join:
- People who have previously had, or are planning to have, surgery on their upper airway for sleep apnea, or major surgery on their ears, nose, or throat.
- People who have significant structural differences in the face or skull that may affect their breathing.
- People whose sleep apnea is primarily caused by the brain not sending proper signals to breathe (central sleep apnea, 50% or more), or who have a specific breathing pattern during sleep called Cheyne Stokes Respiration.
- People currently using any device or treatment for sleep apnea (such as a CPAP machine or mouth device) unless they are willing to stop using it before and throughout the study.
- People with certain breathing conditions such as obesity-related breathing problems during the day, nerve or muscle diseases, or other health conditions that the study doctor believes could affect the trial results (confirm with trial site).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: MD, Amgen
Phone: 866-572-6436
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
3 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Change in Apnea-hypopnea Index (AHI) from baseline at Week 52
Can't join this trial?
Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.